comekibart

What stands out

• Same target as Dupixent
• Binds to IL-4 receptor, the docking point for both the IL-4 and IL-13 signals
• Injection every 2, 4 or 8 weeks in trials

History

Earliest recorded event: Aug 31, 2022. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

• Apr 29, 2026Phase 2 trial completedA Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis ClinicalTrials.gov NCT07103174
• Apr 20, 2026Phase 3 trial postedA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT07540442
• Mar 18, 2026Phase 3 trial postedA Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis ClinicalTrials.gov NCT07479615
• Mar 9, 2026Phase 2 main data collectedA Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis ClinicalTrials.gov NCT07103174
• Jun 30, 2025Phase 2 trial startedA Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis ClinicalTrials.gov NCT07103174
• Jul 19, 2024Phase 1/2 trial startedIB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients ClinicalTrials.gov NCT06765005
• Jan 13, 2024Phase 3 trial started · Status not confirmed by the sponsorStudy of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis ClinicalTrials.gov NCT06026891
• Sep 22, 2023Phase 2 main data collected · Status not confirmed by the sponsorA Study of MG-K10 in Subjects With Atopic Dermatitis ClinicalTrials.gov NCT05466877
• Aug 31, 2022Phase 2 trial started · Status not confirmed by the sponsorA Study of MG-K10 in Subjects With Atopic Dermatitis ClinicalTrials.gov NCT05466877

Sources

Trials

• NCT05466877
• NCT06026891
• NCT06765005
• MG-K10 · NCT07103174
• ADaggio · NCT07479615
• NCT07540442